| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Waldenstrom Macroglobulinemia | 132 | 2024 | 1052 | 33.430 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 42 | 2023 | 1378 | 9.520 |
Why?
|
| Myeloid Differentiation Factor 88 | 52 | 2024 | 571 | 8.170 |
Why?
|
| Adenine | 45 | 2024 | 936 | 6.950 |
Why?
|
| Receptors, CXCR4 | 32 | 2022 | 726 | 6.050 |
Why?
|
| Piperidines | 48 | 2024 | 1602 | 5.420 |
Why?
|
| Pyrazoles | 38 | 2024 | 1972 | 5.380 |
Why?
|
| Lymphoma, B-Cell | 13 | 2024 | 931 | 4.800 |
Why?
|
| Pyrimidines | 39 | 2024 | 2942 | 4.800 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 58 | 2023 | 11524 | 4.100 |
Why?
|
| Lymphoma, AIDS-Related | 11 | 2016 | 84 | 3.710 |
Why?
|
| Protein Kinase Inhibitors | 29 | 2023 | 5535 | 3.300 |
Why?
|
| Immunoglobulin M | 23 | 2023 | 1537 | 3.280 |
Why?
|
| Antineoplastic Agents | 41 | 2023 | 13695 | 3.010 |
Why?
|
| Multiple Myeloma | 31 | 2023 | 5181 | 2.950 |
Why?
|
| Epstein-Barr Virus Infections | 11 | 2022 | 570 | 2.880 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 8 | 2023 | 134 | 2.640 |
Why?
|
| Vincristine | 21 | 2022 | 1039 | 2.160 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 7 | 2022 | 180 | 2.110 |
Why?
|
| Lymphoma, Non-Hodgkin | 12 | 2015 | 1381 | 2.020 |
Why?
|
| Antigens, CD20 | 10 | 2019 | 199 | 2.000 |
Why?
|
| Cyclophosphamide | 25 | 2023 | 2242 | 1.940 |
Why?
|
| Prognosis | 67 | 2023 | 29063 | 1.750 |
Why?
|
| Doxorubicin | 23 | 2022 | 2234 | 1.740 |
Why?
|
| SEER Program | 12 | 2018 | 1508 | 1.740 |
Why?
|
| Prednisone | 19 | 2022 | 1574 | 1.710 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 11 | 2018 | 693 | 1.660 |
Why?
|
| Lymphoproliferative Disorders | 5 | 2023 | 523 | 1.610 |
Why?
|
| Mutation | 46 | 2023 | 29786 | 1.500 |
Why?
|
| Herpesvirus 4, Human | 11 | 2022 | 1041 | 1.500 |
Why?
|
| Humans | 298 | 2024 | 744343 | 1.490 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 5 | 2021 | 166 | 1.470 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 5 | 2022 | 177 | 1.450 |
Why?
|
| Hodgkin Disease | 6 | 2016 | 1415 | 1.450 |
Why?
|
| Paraproteinemias | 5 | 2022 | 246 | 1.400 |
Why?
|
| Aged | 119 | 2024 | 163280 | 1.380 |
Why?
|
| B-Lymphocytes | 13 | 2023 | 4665 | 1.300 |
Why?
|
| Lymphoma | 10 | 2021 | 1877 | 1.270 |
Why?
|
| Lymphoma, Primary Effusion | 3 | 2020 | 17 | 1.270 |
Why?
|
| Survival Rate | 28 | 2021 | 12788 | 1.260 |
Why?
|
| Survival Analysis | 29 | 2020 | 10252 | 1.250 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 9 | 2023 | 1596 | 1.230 |
Why?
|
| Middle Aged | 119 | 2022 | 213383 | 1.200 |
Why?
|
| Neoplasms, Second Primary | 6 | 2020 | 1061 | 1.190 |
Why?
|
| Aged, 80 and over | 62 | 2022 | 57776 | 1.170 |
Why?
|
| Plasma Cells | 7 | 2023 | 591 | 1.150 |
Why?
|
| Treatment Outcome | 52 | 2023 | 63114 | 1.120 |
Why?
|
| Herpesvirus 8, Human | 3 | 2020 | 258 | 1.110 |
Why?
|
| Lymphocytes | 4 | 2020 | 2617 | 1.110 |
Why?
|
| Lymphoma, Large-Cell, Immunoblastic | 3 | 2011 | 26 | 1.100 |
Why?
|
| Bone Marrow | 13 | 2023 | 2948 | 1.060 |
Why?
|
| Male | 138 | 2023 | 350118 | 1.040 |
Why?
|
| Neoplasm Proteins | 6 | 2021 | 3703 | 1.040 |
Why?
|
| Central Nervous System Neoplasms | 5 | 2016 | 895 | 1.030 |
Why?
|
| Disease-Free Survival | 20 | 2020 | 6895 | 0.990 |
Why?
|
| Leukemia, Plasma Cell | 3 | 2022 | 48 | 0.990 |
Why?
|
| Quinazolinones | 3 | 2016 | 221 | 0.970 |
Why?
|
| Disease Management | 10 | 2021 | 2459 | 0.970 |
Why?
|
| Sulfonamides | 3 | 2024 | 1938 | 0.960 |
Why?
|
| Female | 134 | 2023 | 380194 | 0.960 |
Why?
|
| Antibodies, Monoclonal | 13 | 2023 | 9274 | 0.940 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 4 | 2021 | 169 | 0.940 |
Why?
|
| Adult | 95 | 2023 | 214055 | 0.920 |
Why?
|
| Antiretroviral Therapy, Highly Active | 8 | 2016 | 1873 | 0.910 |
Why?
|
| Salvage Therapy | 7 | 2022 | 1275 | 0.900 |
Why?
|
| Antineoplastic Agents, Alkylating | 4 | 2020 | 627 | 0.890 |
Why?
|
| Protein-Tyrosine Kinases | 7 | 2023 | 2455 | 0.870 |
Why?
|
| Erythrocyte Indices | 2 | 2023 | 146 | 0.870 |
Why?
|
| Burkitt Lymphoma | 3 | 2013 | 327 | 0.870 |
Why?
|
| Purines | 3 | 2016 | 594 | 0.860 |
Why?
|
| Kaplan-Meier Estimate | 15 | 2020 | 6538 | 0.850 |
Why?
|
| Molecular Targeted Therapy | 6 | 2023 | 2727 | 0.840 |
Why?
|
| Ifosfamide | 1 | 2022 | 228 | 0.810 |
Why?
|
| Neutrophils | 4 | 2020 | 3719 | 0.810 |
Why?
|
| Hyponatremia | 2 | 2016 | 298 | 0.790 |
Why?
|
| Leukemia | 4 | 2014 | 1511 | 0.780 |
Why?
|
| Herpesviridae Infections | 2 | 2020 | 277 | 0.760 |
Why?
|
| Immunotherapy | 8 | 2023 | 4445 | 0.760 |
Why?
|
| Blood Viscosity | 2 | 2019 | 124 | 0.750 |
Why?
|
| HIV Infections | 14 | 2023 | 16718 | 0.750 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2023 | 233 | 0.740 |
Why?
|
| Leukemia, Myeloid, Acute | 7 | 2015 | 3523 | 0.730 |
Why?
|
| Proto-Oncogene Proteins c-hck | 5 | 2022 | 46 | 0.730 |
Why?
|
| Etoposide | 5 | 2022 | 641 | 0.700 |
Why?
|
| Pyrazines | 5 | 2021 | 1230 | 0.680 |
Why?
|
| Human T-lymphotropic virus 1 | 2 | 2021 | 140 | 0.650 |
Why?
|
| Mutation, Missense | 2 | 2019 | 2564 | 0.640 |
Why?
|
| Pleural Effusion, Malignant | 2 | 2016 | 101 | 0.630 |
Why?
|
| Stem Cell Transplantation | 6 | 2018 | 1620 | 0.630 |
Why?
|
| Retrospective Studies | 44 | 2023 | 77449 | 0.620 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2017 | 2942 | 0.620 |
Why?
|
| Nervous System | 1 | 2021 | 554 | 0.610 |
Why?
|
| Neoplasm Staging | 17 | 2019 | 11031 | 0.580 |
Why?
|
| Neutropenia | 2 | 2012 | 895 | 0.570 |
Why?
|
| beta 2-Microglobulin | 3 | 2020 | 315 | 0.560 |
Why?
|
| Hematologic Neoplasms | 4 | 2014 | 1832 | 0.550 |
Why?
|
| HIV Seropositivity | 2 | 2013 | 971 | 0.540 |
Why?
|
| Incidence | 17 | 2021 | 20947 | 0.530 |
Why?
|
| Combined Modality Therapy | 12 | 2020 | 8642 | 0.530 |
Why?
|
| Smoking | 4 | 2014 | 8987 | 0.530 |
Why?
|
| Signal Transduction | 14 | 2022 | 23403 | 0.520 |
Why?
|
| Anti-Retroviral Agents | 2 | 2016 | 1715 | 0.520 |
Why?
|
| Daunorubicin | 1 | 2015 | 158 | 0.510 |
Why?
|
| Dexamethasone | 6 | 2023 | 1951 | 0.490 |
Why?
|
| Boronic Acids | 3 | 2015 | 965 | 0.480 |
Why?
|
| Skin Neoplasms | 4 | 2021 | 5686 | 0.480 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2016 | 424 | 0.480 |
Why?
|
| von Willebrand Factor | 1 | 2018 | 669 | 0.470 |
Why?
|
| Drug Tolerance | 1 | 2015 | 376 | 0.470 |
Why?
|
| Age Factors | 10 | 2018 | 18370 | 0.470 |
Why?
|
| Myxoma | 1 | 2014 | 130 | 0.460 |
Why?
|
| Latin America | 4 | 2023 | 381 | 0.460 |
Why?
|
| Acidosis, Lactic | 1 | 2015 | 142 | 0.460 |
Why?
|
| Withholding Treatment | 1 | 2018 | 599 | 0.460 |
Why?
|
| Disease Progression | 11 | 2021 | 13284 | 0.450 |
Why?
|
| Erythrocyte Membrane | 1 | 2014 | 442 | 0.440 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2018 | 632 | 0.440 |
Why?
|
| Hyperammonemia | 1 | 2013 | 76 | 0.430 |
Why?
|
| Pleural Cavity | 1 | 2012 | 22 | 0.430 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2014 | 207 | 0.420 |
Why?
|
| Peritoneal Cavity | 1 | 2012 | 148 | 0.420 |
Why?
|
| Follow-Up Studies | 18 | 2021 | 39050 | 0.410 |
Why?
|
| Central Nervous System Diseases | 1 | 2016 | 518 | 0.410 |
Why?
|
| Proportional Hazards Models | 8 | 2021 | 12354 | 0.410 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2020 | 2232 | 0.400 |
Why?
|
| Immunoblastic Lymphadenopathy | 1 | 2011 | 35 | 0.400 |
Why?
|
| Peru | 5 | 2021 | 881 | 0.400 |
Why?
|
| Young Adult | 23 | 2022 | 56430 | 0.400 |
Why?
|
| Prospective Studies | 17 | 2023 | 53288 | 0.390 |
Why?
|
| Leukocyte Count | 1 | 2015 | 1588 | 0.390 |
Why?
|
| Insurance Claim Review | 1 | 2016 | 720 | 0.390 |
Why?
|
| Dura Mater | 1 | 2013 | 291 | 0.380 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 9 | 2022 | 5442 | 0.380 |
Why?
|
| Heart Neoplasms | 1 | 2014 | 374 | 0.380 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2012 | 573 | 0.380 |
Why?
|
| Immunophenotyping | 5 | 2021 | 1880 | 0.380 |
Why?
|
| Thalidomide | 2 | 2022 | 890 | 0.380 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2014 | 604 | 0.370 |
Why?
|
| HIV Seronegativity | 1 | 2011 | 211 | 0.360 |
Why?
|
| Sarcoma, Myeloid | 1 | 2010 | 59 | 0.360 |
Why?
|
| Fatty Acids | 2 | 2014 | 1809 | 0.350 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2017 | 685 | 0.350 |
Why?
|
| Risk Factors | 22 | 2022 | 72290 | 0.340 |
Why?
|
| Kidney Diseases | 2 | 2021 | 2149 | 0.340 |
Why?
|
| Diagnosis, Differential | 8 | 2022 | 12959 | 0.340 |
Why?
|
| Lymphoma, Follicular | 1 | 2013 | 435 | 0.340 |
Why?
|
| Fatal Outcome | 4 | 2021 | 1850 | 0.330 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2021 | 5172 | 0.320 |
Why?
|
| Mouth | 1 | 2011 | 374 | 0.320 |
Why?
|
| Cohort Studies | 14 | 2021 | 40561 | 0.320 |
Why?
|
| Biopsy | 6 | 2018 | 6756 | 0.320 |
Why?
|
| Immunoglobulin G | 4 | 2018 | 4560 | 0.320 |
Why?
|
| Lymphopenia | 1 | 2010 | 285 | 0.320 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2021 | 1434 | 0.320 |
Why?
|
| Boron Compounds | 2 | 2020 | 178 | 0.310 |
Why?
|
| Clinical Trials as Topic | 8 | 2020 | 7913 | 0.310 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2009 | 183 | 0.310 |
Why?
|
| Albumins | 1 | 2010 | 569 | 0.310 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2021 | 3597 | 0.300 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2010 | 442 | 0.300 |
Why?
|
| Chile | 3 | 2022 | 237 | 0.300 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2009 | 255 | 0.300 |
Why?
|
| Kidney | 2 | 2021 | 7186 | 0.300 |
Why?
|
| Syndrome | 4 | 2018 | 3251 | 0.300 |
Why?
|
| Obesity | 3 | 2015 | 12745 | 0.300 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2011 | 1369 | 0.290 |
Why?
|
| Immunoconjugates | 1 | 2014 | 901 | 0.280 |
Why?
|
| United States | 18 | 2021 | 69872 | 0.280 |
Why?
|
| Case-Control Studies | 11 | 2020 | 21746 | 0.280 |
Why?
|
| Algorithms | 4 | 2017 | 13881 | 0.280 |
Why?
|
| Lymphocyte Count | 4 | 2021 | 793 | 0.280 |
Why?
|
| Glycine | 2 | 2020 | 671 | 0.270 |
Why?
|
| Registries | 3 | 2020 | 8089 | 0.270 |
Why?
|
| Databases, Factual | 4 | 2017 | 7729 | 0.270 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 2 | 2021 | 142 | 0.270 |
Why?
|
| Medical Oncology | 7 | 2023 | 2265 | 0.270 |
Why?
|
| Remission Induction | 6 | 2014 | 2386 | 0.270 |
Why?
|
| Amino Acid Substitution | 4 | 2019 | 1791 | 0.270 |
Why?
|
| Amyloidosis | 2 | 2023 | 795 | 0.260 |
Why?
|
| Mouth Neoplasms | 1 | 2011 | 601 | 0.260 |
Why?
|
| Transplantation, Autologous | 6 | 2022 | 2124 | 0.260 |
Why?
|
| Drug Resistance | 2 | 2023 | 1609 | 0.260 |
Why?
|
| Erythrocyte Transfusion | 1 | 2010 | 565 | 0.260 |
Why?
|
| Lymph Nodes | 5 | 2021 | 3474 | 0.260 |
Why?
|
| Clostridium Infections | 1 | 2012 | 548 | 0.250 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2009 | 233 | 0.250 |
Why?
|
| Neoplasms | 5 | 2016 | 21683 | 0.250 |
Why?
|
| Benzamides | 2 | 2021 | 1379 | 0.250 |
Why?
|
| Adolescent | 18 | 2022 | 85781 | 0.250 |
Why?
|
| Genomics | 5 | 2021 | 5720 | 0.250 |
Why?
|
| Chromosome Deletion | 2 | 2020 | 1401 | 0.240 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2022 | 934 | 0.240 |
Why?
|
| Overweight | 2 | 2013 | 2371 | 0.240 |
Why?
|
| Brain Diseases | 1 | 2013 | 1563 | 0.240 |
Why?
|
| Bleomycin | 2 | 2014 | 512 | 0.220 |
Why?
|
| Biomedical Research | 1 | 2018 | 3309 | 0.220 |
Why?
|
| Vinblastine | 2 | 2014 | 502 | 0.220 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2015 | 2245 | 0.210 |
Why?
|
| Hematology | 2 | 2019 | 221 | 0.210 |
Why?
|
| Plasmacytoma | 2 | 2020 | 183 | 0.210 |
Why?
|
| POEMS Syndrome | 1 | 2021 | 19 | 0.210 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2014 | 2104 | 0.200 |
Why?
|
| Population Surveillance | 4 | 2017 | 2616 | 0.200 |
Why?
|
| Cyanosis | 1 | 2021 | 83 | 0.200 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 4149 | 0.200 |
Why?
|
| CD40 Ligand | 1 | 2023 | 526 | 0.200 |
Why?
|
| Dacarbazine | 2 | 2014 | 566 | 0.200 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2021 | 173 | 0.190 |
Why?
|
| Recurrence | 5 | 2019 | 8340 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2021 | 10943 | 0.190 |
Why?
|
| Rhode Island | 2 | 2013 | 347 | 0.190 |
Why?
|
| Age of Onset | 2 | 2018 | 3271 | 0.190 |
Why?
|
| Vidarabine | 2 | 2013 | 345 | 0.190 |
Why?
|
| Immunohistochemistry | 4 | 2021 | 11366 | 0.190 |
Why?
|
| Review Literature as Topic | 2 | 2013 | 336 | 0.190 |
Why?
|
| Biology | 1 | 2022 | 294 | 0.180 |
Why?
|
| Antigens, Neoplasm | 1 | 2008 | 1988 | 0.180 |
Why?
|
| Paraproteins | 1 | 2020 | 39 | 0.180 |
Why?
|
| Primary Health Care | 1 | 2016 | 4558 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2023 | 9239 | 0.180 |
Why?
|
| T-Lymphocytes | 2 | 2023 | 10180 | 0.180 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2011 | 2559 | 0.170 |
Why?
|
| Chromosome Aberrations | 2 | 2016 | 1813 | 0.170 |
Why?
|
| Herpes Zoster | 1 | 2022 | 264 | 0.170 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2021 | 2938 | 0.170 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2020 | 1270 | 0.170 |
Why?
|
| Edema | 1 | 2023 | 789 | 0.170 |
Why?
|
| Therapies, Investigational | 1 | 2020 | 112 | 0.170 |
Why?
|
| Carboplatin | 1 | 2022 | 801 | 0.170 |
Why?
|
| Odds Ratio | 3 | 2019 | 9849 | 0.170 |
Why?
|
| Portraits as Topic | 1 | 2018 | 33 | 0.170 |
Why?
|
| Flaviviridae | 1 | 2018 | 9 | 0.170 |
Why?
|
| Flaviviridae Infections | 1 | 2018 | 7 | 0.170 |
Why?
|
| Point Mutation | 2 | 2021 | 1623 | 0.170 |
Why?
|
| Colorectal Neoplasms | 2 | 2016 | 6773 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2020 | 380 | 0.160 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2012 | 2988 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2020 | 460 | 0.160 |
Why?
|
| Models, Biological | 1 | 2014 | 9583 | 0.160 |
Why?
|
| Pleura | 1 | 2019 | 235 | 0.160 |
Why?
|
| Consensus | 3 | 2023 | 2959 | 0.160 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 8863 | 0.160 |
Why?
|
| Cell Proliferation | 3 | 2022 | 10481 | 0.160 |
Why?
|
| Medicare | 4 | 2020 | 6566 | 0.150 |
Why?
|
| Amyloid | 1 | 2023 | 795 | 0.150 |
Why?
|
| Logistic Models | 3 | 2020 | 13408 | 0.150 |
Why?
|
| Wounds and Injuries | 1 | 2010 | 2400 | 0.150 |
Why?
|
| Chemokine CXCL13 | 1 | 2017 | 54 | 0.150 |
Why?
|
| Alkylating Agents | 1 | 2017 | 139 | 0.150 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 5034 | 0.150 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2017 | 78 | 0.150 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2018 | 249 | 0.150 |
Why?
|
| Risk Assessment | 6 | 2020 | 23338 | 0.150 |
Why?
|
| Autoimmune Diseases | 1 | 2009 | 2133 | 0.150 |
Why?
|
| Sex Factors | 3 | 2017 | 10397 | 0.140 |
Why?
|
| Pathology, Molecular | 1 | 2020 | 326 | 0.140 |
Why?
|
| Plasmapheresis | 1 | 2017 | 211 | 0.140 |
Why?
|
| von Willebrand Diseases | 1 | 2018 | 127 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2018 | 8428 | 0.140 |
Why?
|
| Paracrine Communication | 1 | 2018 | 277 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 7279 | 0.140 |
Why?
|
| London | 1 | 2016 | 233 | 0.140 |
Why?
|
| Animals | 11 | 2021 | 168757 | 0.140 |
Why?
|
| Ligands | 1 | 2023 | 3282 | 0.140 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2022 | 2916 | 0.140 |
Why?
|
| Multivariate Analysis | 4 | 2015 | 12245 | 0.130 |
Why?
|
| Infectious Mononucleosis | 1 | 2016 | 131 | 0.130 |
Why?
|
| Amyloid Neuropathies, Familial | 1 | 2018 | 138 | 0.130 |
Why?
|
| Body Surface Area | 1 | 2015 | 198 | 0.130 |
Why?
|
| Histocytochemistry | 1 | 2016 | 719 | 0.130 |
Why?
|
| Hydroa Vacciniforme | 1 | 2014 | 3 | 0.130 |
Why?
|
| Bone and Bones | 2 | 2017 | 2575 | 0.130 |
Why?
|
| Lung Injury | 1 | 2020 | 436 | 0.130 |
Why?
|
| Protein Multimerization | 2 | 2017 | 970 | 0.130 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2021 | 1660 | 0.130 |
Why?
|
| Liver Function Tests | 1 | 2016 | 528 | 0.130 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2011 | 1375 | 0.130 |
Why?
|
| Neoplasms, Adnexal and Skin Appendage | 1 | 2014 | 25 | 0.120 |
Why?
|
| Time Factors | 5 | 2021 | 40075 | 0.120 |
Why?
|
| Leucine | 1 | 2016 | 561 | 0.120 |
Why?
|
| Virus Activation | 1 | 2016 | 319 | 0.120 |
Why?
|
| Translocation, Genetic | 2 | 2020 | 1420 | 0.120 |
Why?
|
| Proline | 1 | 2016 | 458 | 0.120 |
Why?
|
| Subcutaneous Tissue | 1 | 2014 | 135 | 0.120 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 13102 | 0.120 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 684 | 0.120 |
Why?
|
| Databases, Bibliographic | 1 | 2014 | 128 | 0.120 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2024 | 2268 | 0.120 |
Why?
|
| HTLV-I Infections | 1 | 2014 | 101 | 0.120 |
Why?
|
| Toll-Like Receptors | 1 | 2017 | 592 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 35421 | 0.110 |
Why?
|
| Breast Neoplasms | 3 | 2016 | 20822 | 0.110 |
Why?
|
| Codon, Nonsense | 1 | 2014 | 281 | 0.110 |
Why?
|
| Organ Specificity | 2 | 2019 | 2008 | 0.110 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2013 | 46 | 0.110 |
Why?
|
| Skin Diseases | 1 | 2022 | 1065 | 0.110 |
Why?
|
| Propensity Score | 1 | 2020 | 1781 | 0.110 |
Why?
|
| Risk | 2 | 2016 | 9687 | 0.110 |
Why?
|
| Parvoviridae Infections | 1 | 2012 | 35 | 0.110 |
Why?
|
| DNA Mutational Analysis | 2 | 2021 | 4186 | 0.110 |
Why?
|
| Parvovirus B19, Human | 1 | 2012 | 38 | 0.110 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2016 | 548 | 0.110 |
Why?
|
| Frameshift Mutation | 1 | 2014 | 399 | 0.110 |
Why?
|
| Eye Neoplasms | 1 | 2014 | 313 | 0.110 |
Why?
|
| Cerebrospinal Fluid | 1 | 2015 | 534 | 0.110 |
Why?
|
| Immunoglobulin E | 1 | 2018 | 1463 | 0.110 |
Why?
|
| Hypovolemia | 1 | 2012 | 45 | 0.110 |
Why?
|
| Tattooing | 1 | 2012 | 58 | 0.110 |
Why?
|
| Arginine Vasopressin | 1 | 2012 | 130 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 11124 | 0.100 |
Why?
|
| Lymphocytosis | 1 | 2013 | 119 | 0.100 |
Why?
|
| Splenic Neoplasms | 1 | 2012 | 100 | 0.100 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 2012 | 61 | 0.100 |
Why?
|
| Advisory Committees | 1 | 2016 | 775 | 0.100 |
Why?
|
| Receptors, Vasopressin | 1 | 2012 | 112 | 0.100 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2016 | 388 | 0.100 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 625 | 0.100 |
Why?
|
| Immunocompetence | 1 | 2011 | 137 | 0.100 |
Why?
|
| DNA Copy Number Variations | 1 | 2020 | 1941 | 0.100 |
Why?
|
| Asia | 1 | 2013 | 610 | 0.100 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 3586 | 0.100 |
Why?
|
| Blood Proteins | 1 | 2016 | 1124 | 0.100 |
Why?
|
| Viral Load | 2 | 2011 | 3299 | 0.090 |
Why?
|
| MAP Kinase Signaling System | 1 | 2018 | 1526 | 0.090 |
Why?
|
| Epidemiologic Studies | 1 | 2014 | 676 | 0.090 |
Why?
|
| Anemia, Aplastic | 1 | 2012 | 226 | 0.090 |
Why?
|
| Leukemic Infiltration | 1 | 2010 | 48 | 0.090 |
Why?
|
| Nervous System Diseases | 1 | 2021 | 1622 | 0.090 |
Why?
|
| Breast Implants | 1 | 2013 | 387 | 0.090 |
Why?
|
| Benzazepines | 1 | 2012 | 326 | 0.090 |
Why?
|
| Blood-Brain Barrier | 1 | 2016 | 1017 | 0.090 |
Why?
|
| Hepatitis B virus | 1 | 2013 | 513 | 0.090 |
Why?
|
| Leukapheresis | 1 | 2009 | 131 | 0.090 |
Why?
|
| Quality of Life | 2 | 2022 | 12804 | 0.090 |
Why?
|
| Hospitals | 1 | 2023 | 3952 | 0.090 |
Why?
|
| Public Health | 1 | 2022 | 2603 | 0.090 |
Why?
|
| Antibodies, Neoplasm | 1 | 2011 | 286 | 0.090 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 1157 | 0.090 |
Why?
|
| Cell Transformation, Viral | 1 | 2011 | 565 | 0.090 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 1671 | 0.080 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2012 | 648 | 0.080 |
Why?
|
| Radiotherapy | 1 | 2016 | 1533 | 0.080 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2010 | 215 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 1956 | 0.080 |
Why?
|
| Pregnancy Trimesters | 1 | 2009 | 192 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 9959 | 0.080 |
Why?
|
| False Positive Reactions | 1 | 2011 | 981 | 0.080 |
Why?
|
| Graves Disease | 1 | 2010 | 242 | 0.080 |
Why?
|
| Oligopeptides | 1 | 2014 | 1189 | 0.080 |
Why?
|
| Lung | 2 | 2019 | 9856 | 0.080 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2010 | 131 | 0.080 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2012 | 365 | 0.080 |
Why?
|
| Membrane Proteins | 2 | 2016 | 7880 | 0.080 |
Why?
|
| Pesticides | 1 | 2011 | 287 | 0.080 |
Why?
|
| Antiemetics | 1 | 2009 | 177 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 11725 | 0.080 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 1788 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2010 | 15295 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 2948 | 0.080 |
Why?
|
| Protein Binding | 2 | 2017 | 9386 | 0.080 |
Why?
|
| Apoptosis | 4 | 2020 | 9727 | 0.080 |
Why?
|
| Hepatitis B | 1 | 2013 | 695 | 0.080 |
Why?
|
| Pericardium | 1 | 2012 | 667 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 3616 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 4933 | 0.080 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2011 | 890 | 0.080 |
Why?
|
| Down-Regulation | 1 | 2015 | 3002 | 0.070 |
Why?
|
| Sirolimus | 1 | 2015 | 1564 | 0.070 |
Why?
|
| Periodicals as Topic | 1 | 2018 | 1432 | 0.070 |
Why?
|
| Cluster Analysis | 1 | 2014 | 2715 | 0.070 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2013 | 1038 | 0.070 |
Why?
|
| Phenotype | 2 | 2016 | 16365 | 0.070 |
Why?
|
| Boston | 2 | 2019 | 9313 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 2529 | 0.070 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2009 | 317 | 0.070 |
Why?
|
| Patient Selection | 2 | 2018 | 4215 | 0.070 |
Why?
|
| Sodium | 1 | 2012 | 1623 | 0.070 |
Why?
|
| NF-kappa B | 3 | 2020 | 2499 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2022 | 3143 | 0.070 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2010 | 550 | 0.070 |
Why?
|
| Gene Expression | 1 | 2019 | 7799 | 0.070 |
Why?
|
| Antibody Specificity | 1 | 2008 | 1095 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2015 | 2016 | 0.070 |
Why?
|
| Europe | 1 | 2013 | 3339 | 0.070 |
Why?
|
| Genotype | 2 | 2017 | 12951 | 0.070 |
Why?
|
| Skin | 1 | 2019 | 4364 | 0.070 |
Why?
|
| Drug Interactions | 1 | 2010 | 1460 | 0.070 |
Why?
|
| Truth Disclosure | 1 | 2009 | 436 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 2503 | 0.070 |
Why?
|
| Membrane Glycoproteins | 1 | 2016 | 3768 | 0.070 |
Why?
|
| Child | 6 | 2018 | 77709 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2022 | 4262 | 0.060 |
Why?
|
| Thyroidectomy | 1 | 2010 | 879 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 17446 | 0.060 |
Why?
|
| Fever | 1 | 2012 | 1616 | 0.060 |
Why?
|
| Child, Preschool | 4 | 2010 | 41006 | 0.060 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2009 | 582 | 0.060 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2014 | 1352 | 0.060 |
Why?
|
| Iron | 1 | 2012 | 1774 | 0.060 |
Why?
|
| Abortion, Induced | 1 | 2009 | 458 | 0.060 |
Why?
|
| Regression Analysis | 1 | 2013 | 6459 | 0.060 |
Why?
|
| Clinical Protocols | 1 | 2009 | 1462 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2016 | 2987 | 0.060 |
Why?
|
| Central Nervous System | 2 | 2022 | 1357 | 0.060 |
Why?
|
| Host-Pathogen Interactions | 1 | 2012 | 1477 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2015 | 3589 | 0.050 |
Why?
|
| Comorbidity | 1 | 2017 | 10388 | 0.050 |
Why?
|
| World Health Organization | 1 | 2008 | 1318 | 0.050 |
Why?
|
| Cross Infection | 1 | 2012 | 1416 | 0.050 |
Why?
|
| Cell Line, Tumor | 4 | 2021 | 16689 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2018 | 3752 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 4554 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 2716 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2010 | 4776 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3133 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3240 | 0.050 |
Why?
|
| Cell Survival | 3 | 2018 | 5882 | 0.050 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 3086 | 0.050 |
Why?
|
| Inflammation | 1 | 2021 | 10638 | 0.050 |
Why?
|
| Cesarean Section | 1 | 2009 | 1365 | 0.050 |
Why?
|
| Argentina | 1 | 2021 | 232 | 0.050 |
Why?
|
| Colombia | 1 | 2021 | 258 | 0.050 |
Why?
|
| Ulcer | 1 | 2022 | 209 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2021 | 6314 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 2219 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2008 | 1584 | 0.050 |
Why?
|
| Cell Line | 2 | 2018 | 15997 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 13989 | 0.050 |
Why?
|
| Phospholipase C gamma | 1 | 2020 | 128 | 0.040 |
Why?
|
| Acute Disease | 1 | 2010 | 7149 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2010 | 5974 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 19905 | 0.040 |
Why?
|
| Infant | 3 | 2010 | 35136 | 0.040 |
Why?
|
| Molecular Biology | 1 | 2023 | 596 | 0.040 |
Why?
|
| Immunologic Factors | 2 | 2019 | 1580 | 0.040 |
Why?
|
| src-Family Kinases | 1 | 2022 | 551 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2009 | 2795 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 6234 | 0.040 |
Why?
|
| Mice | 3 | 2021 | 81183 | 0.040 |
Why?
|
| Upper Extremity | 1 | 2023 | 648 | 0.040 |
Why?
|
| Hemoglobins | 2 | 2015 | 1534 | 0.040 |
Why?
|
| Pneumocystis carinii | 1 | 2018 | 74 | 0.040 |
Why?
|
| Technetium | 1 | 2018 | 334 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2015 | 12720 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 5221 | 0.040 |
Why?
|
| Cytogenetic Analysis | 1 | 2018 | 295 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2009 | 2291 | 0.040 |
Why?
|
| Interferon-alpha | 1 | 2021 | 895 | 0.040 |
Why?
|
| Calcium | 1 | 2010 | 5756 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2021 | 1878 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2023 | 2649 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2009 | 3229 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2021 | 2716 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 20129 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2019 | 551 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2016 | 563 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 1782 | 0.030 |
Why?
|
| Mutant Proteins | 1 | 2016 | 500 | 0.030 |
Why?
|
| Exosomes | 1 | 2018 | 417 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2018 | 2031 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2016 | 474 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 7181 | 0.030 |
Why?
|
| HIV-1 | 1 | 2010 | 6939 | 0.030 |
Why?
|
| Cytokines | 2 | 2018 | 7322 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2014 | 464 | 0.030 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2016 | 651 | 0.030 |
Why?
|
| Hospitalization | 1 | 2012 | 10262 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 602 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2015 | 695 | 0.020 |
Why?
|
| Antigens, CD19 | 1 | 2014 | 380 | 0.020 |
Why?
|
| Serum | 1 | 2012 | 214 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2019 | 1376 | 0.020 |
Why?
|
| South America | 1 | 2011 | 181 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 2203 | 0.020 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2016 | 783 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2013 | 497 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2015 | 1792 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2016 | 3129 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2008 | 5751 | 0.020 |
Why?
|
| Prednisolone | 1 | 2011 | 334 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2016 | 1783 | 0.020 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2011 | 128 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2009 | 25625 | 0.020 |
Why?
|
| Watchful Waiting | 1 | 2013 | 492 | 0.020 |
Why?
|
| DNA Repair | 1 | 2018 | 2046 | 0.020 |
Why?
|
| Plasma Exchange | 1 | 2010 | 152 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 1889 | 0.020 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2010 | 116 | 0.020 |
Why?
|
| Device Removal | 1 | 2013 | 656 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2018 | 2703 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2014 | 3701 | 0.020 |
Why?
|
| Drug Discovery | 1 | 2016 | 1058 | 0.020 |
Why?
|
| Pregnancy | 1 | 2009 | 29144 | 0.020 |
Why?
|
| Interferon Regulatory Factors | 1 | 2009 | 270 | 0.020 |
Why?
|
| Vitamin B 12 | 1 | 2010 | 527 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2022 | 4599 | 0.020 |
Why?
|
| Plasma | 1 | 2010 | 575 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2016 | 3200 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 6171 | 0.020 |
Why?
|
| Cardiomyopathies | 1 | 2018 | 1912 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 2297 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2016 | 5456 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 3647 | 0.020 |
Why?
|
| Alleles | 1 | 2016 | 6933 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 6489 | 0.020 |
Why?
|
| Family | 1 | 2016 | 3147 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 5867 | 0.020 |
Why?
|
| Breast | 1 | 2013 | 1969 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 4803 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2014 | 3494 | 0.010 |
Why?
|
| Liver | 1 | 2019 | 7474 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2016 | 5097 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 15076 | 0.010 |
Why?
|
| Graft Survival | 1 | 2013 | 3737 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2016 | 4286 | 0.010 |
Why?
|
| Fellowships and Scholarships | 1 | 2009 | 1076 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2016 | 6544 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2013 | 2957 | 0.010 |
Why?
|
| Data Collection | 1 | 2009 | 3341 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8388 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 15519 | 0.010 |
Why?
|
| Research Design | 1 | 2013 | 5987 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2010 | 4386 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2009 | 3843 | 0.010 |
Why?
|
| Communication | 1 | 2009 | 3749 | 0.010 |
Why?
|